Tres Alchemix is an AI-driven biotechnology company focused on accelerating drug discovery, predicting drug efficacy and etc.
Tres Alchemix has raised $4.4M in total funding. The most recent round was Series A. The last funding was announced in September 2025.
Tres Alchemix's investors include DNX Ventures, WASEDA University Ventures.
Tres Alchemix is headquartered in Hakata, Japan.
Tres Alchemix is an AI-driven biotechnology company focused on accelerating drug discovery, predicting drug efficacy and etc.
Tres Alchemix is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tres Alchemix — Funding & Investors." VCBacked, September 26, 2025, https://www.vcbacked.co/company/tres-alchemix. Accessed August 13, 2026.
VCBacked. (2025). Tres Alchemix — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/tres-alchemix
{{cite web |title=Tres Alchemix — Funding & Investors |url=https://www.vcbacked.co/company/tres-alchemix |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated